Crawford Matthew David – Trademark Portfolio

Entity Type: 01

Crawford Matthew David holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 44 (Medical Services) — 1 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include NEURELLA. The owner is based in Nutley, NJ.

584 Passaic Ave

Nutley, NJ 07110

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

NEURELLA
NEURELLA
Registered 2016

Trademark Classifications

Crawford Matthew David's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

44
Medical Services (1 filing)

Medical services; veterinary services; hygienic and beauty care for human beings or animals

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Crawford Matthew David have?

Crawford Matthew David has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does Crawford Matthew David file in?

Crawford Matthew David files trademarks across 2 Nice Classification classes. The most active classes are Class 44 (Medical Services), Class 5 (Pharmaceuticals). Class 44 covers medical services; veterinary services; hygienic and beauty care for human beings or animals.

What are Crawford Matthew David's most well-known trademarks?

Crawford Matthew David's registered trademark portfolio includes well-known marks such as NEURELLA. These are among 1 currently registered trademark in the portfolio.

What is Crawford Matthew David's trademark registration success rate?

Crawford Matthew David has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.